Nöroloji Klinik Pratiğinde Yeni Oral Antikoagulan İlaçların Kullanımı

Yeni oral antikoagülan ilaçların kullanımı günümüzde gittikçe artmaktadır. Amacımız bu ilaçlarla ilgili bilgi düzeyini arttırmak ve günlük klinik pratikte daha güvenli kullanımını sağlamaktır

Usage of New Oral Anticoagulant Drugs in Clinical Practice of Neurology

It is increased the usage of new oral anticoagulant drugs currently. Our aim is to increase the level of knowledge about these drugs and to ensure the safety usage in daily clinical practice

PDF

___

Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010;115:15-20.
Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: Primary Results of the Prevention of Thromboembolic Events - European Registry in Atrial Fibrillation (PREFERinAF). Europace 2014;16:6-14.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Caediology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J 2014;35:3033-3073.
Patel SI, Obeid H, Matti L, Ramakrishna H, Shamoun FE. Cerebral venous thrombosis: Current and newer anticoagulation treatment options. Neurologist 2015;20:80-88.
Baş DF, Topçuoğlu MA, Arsava EM. Yeni antikogülanlar perspektifinde atrial fibrilasyon ve inme. Türk Beyin Damar Hastalıkları Dergisi 2013;19:35-45.
Stangier J. Clinical pharmacokinetics and Dynamics of the oral direct thrombin inhibitor dabigatran 2008;47:285-295.
Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and in vivo P- glycoprotein rivaroxaban. J Pharmacol Exp Ther 2011;338:372- 380. characteristics
Luettgen JM, Bozarth TA, Bozarth JM, Barbera FA, Lam PY, Quan ML. In vitro evaluation of apixaban, a novel potent, selective and orally bioavailable factor X inhibitor. In proceeding of American Society of Hematology annual meeting exposition 48th, Orlando, Abstr.4130. Washington, DC, 2006.
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010;50:743-753.
Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran reversal. N Engl J Med 20115;373:511-520.